¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü(ÄÁº¥¼ÇȦ)

±³À°ÁÖÁ¦ : 2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 02-2038-7988  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 55ºÐ

¼¼ºÎ¼ö°­·á : 20,000¿ø  

ºñ°í »çÀüµî·Ï -Àü¹®ÀÇ 20,000¿ø -Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø 10,000¿ø -ÇöÀåµî·Ï ºÒ°¡


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:10~09:25 Genetic test of prostate cancer based on clinical practice: When, How, Who? ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:25~09:40 Is PSA sufficient to screening for prostate biopsy? : PSA kinetics, New biomarker (PHI, 4K, etc.) or mpMRI ÀÌÁ¾¼ö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:40~09:55 What is the optimal technique in the era of MR-targeted biopsies and PSMA-PET/CT? ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:55~10:10 Discussion ¼ÛÇÊÇö(¿µ³²ÀÇ´ë)

ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:10~10:30 Coffee Break ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:30~10:45 Which option is considered the most effective for localized low-risk prostate cancer in 2023 : active surveillance, surgery, or radiation therapy? ½ÅÅÃÁØ(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:45~11:00 Changing evidence and guidelines for monitoring during active surveillance À¯¼ºÇö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:00~11:15 Current guidelines of focal therapy in treating prostate cancer ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:15~11:35 Discussion ÀüȲ±Õ(¼º±Õ°üÀÇ´ë)

½Ä»ç 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:35~12:35 Lunch ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:35~12:50 Real clinical advantage of neoadjuvant ADT before radical prostatectomy. ÃÖ¼¼¿µ(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:50~13:05 Treatment guidelines for cN0 and cN1 Źü½Ä(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:05~13:20 Treatment guidelines for pN0 and pN1 after radical prostatectomy ÃÖ¼¼¹Î(°æ»óÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:20~13:40 Discussion ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:40~13:55 What are the prophylactic or treatment options for voiding dysfunction following RP or RT? ¹ÚÇü±Ù(°Ç±¹ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:55~14:10 What are the prophylactic or treatment options for erectile dysfunction following RP or RT? ÇÏÀ±¼®(°æºÏÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:10~14:25 Discussion ¹ÚÀ翵(°í·ÁÀÇ´ë)

ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:25~14:45 Coffee Break ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:45~15:00 Guidelines of radiotherapy for distant metastases ¼­¿øÀÍ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:00~15:15 What is oligometastatic prostate cancer and how should it be treated in the era of  PSMA-PET/CT? ±èÁ¾¿í(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:15~15:30 What should be selected as the first treatment for mHSPC in actual clinical practice? Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:30~15:45 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â ´ëÇѵΰæºÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-10
´ÙÀ½±Û °­µ¿°æÈñ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 2023 Kyung Hee Knee Symposium(ÃÊ·Ï ¹ßÇ¥) : 2023-06-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
63 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Á¦7ȸ Áö¿ª»çȸº´¿ø°ú ÇÔ²²ÇÏ´Â °¨¿°°ü¸® ½ÉÆ÷Áö¿ò : 2018-08-18 0 888 2018-07-28
62 ¼­¿ï 2018 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼ó : 2018-08-18 0 543 2018-07-28
61 ¼­¿ï ´ëÇÑ¿Ü°úÃÊÀ½ÆÄÇÐȸ ÃÊÀ½ÆÄ °Ë»ç ±Ç°í¾È ½ÉÆ÷Áö¾ö : 2018-08-18 0 776 2018-07-28
60 ºÎ»ê 2018³â ´ëÇѼÒÈ­±â¿¬°üÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2018-08-18 0 675 2018-07-28
59 ¼­¿ï ´ëÇÑ»êºÎÀΰúÀÇ»çȸ&Çѱ¹¹ß»ý»ý¹°ÇÐȸ Joint Symposium : 2018-08-18 0 1,081 2018-07-28
58 ¼­¿ï ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18 0 715 2018-07-28
57 ¼­¿ï ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18 0 842 2018-07-28
56 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17 0 857 2018-07-28
55 °­¿ø ´ëÇѽÉÀåÇÐȸ Ç÷°ü¿¬±¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö : 2018-08-17 0 1,286 2018-07-28
54 ¼­¿ï Á߾Ӵ뺴¿ø »êºÎÀΰú žÆÃÊÀ½ÆÄ ¿¬¼Ó°­Á : 2018-08-16 0 659 2018-07-28
53 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À°(ÈĵÎÁúȯ) : 2018-08-16 0 728 2018-07-28
52 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè ¼ö°¡°áÁ¤ : 2018-08-16 0 865 2018-07-28
51 ¼­¿ï Çѱ¹¿ªÇÐȸ Biomarker ¸¦ ÀÌ¿ëÇÑ ¿¬±¸ ¼³°è¿Í ºÐ¼® : 2018-08-14 0 1,277 2018-07-28
50 ¼­¿ï Á¦240ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ : 2018-08-14 0 423 2018-07-28
49 ¼­¿ï Çѱ¹¿ªÇÐȸ MR ±â¹Ý À¯Àüü ¿ªÇבּ¸¿Í °ø°ø°Ç°­ÀÚ·á ±â¹Ý Outcome research : 2018-08-13 0 646 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷